MedPath

Chloroprocaine for Inguinal Herniorrhaphy

Phase 4
Completed
Conditions
Spinal Anesthesia
Interventions
Registration Number
NCT03805503
Lead Sponsor
University Hospital, Ghent
Brief Summary

This study is to determine the minimum effective dose for intrathecal chloroprocaine in inguinal herniorrhaphy in outpatients using a Combined Spinal Epidural (CSE) anesthesia.

Detailed Description

A standard CSE procedure will be conducted in which the patient is placed in an upright sitting position on the side of the operation table and a epidural Tuohy needle 18G will be inserted into L3-L4 interspace via a loss-of-resistance technique. The dura will be punctured using a 27-gauge pencil-point spinal needle and a certain dose of chloroprocaine 1% will be given. After the spinal needle is withdrawn, an epidural catheter will be placed and the epidural needle will be withdrawn. After fixation of catheter the patient will be placed in a supine position.

The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. Each time there will be added 2,5 microgram of sufentanil for prolongation of the analgesia. The testing interval is 2 mg.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Outpatients for unilateral inguinal hernia repair
  • ASA I - II - III
Exclusion Criteria
  • hypersensitivity to amino-ester local anesthetics, para-aminobenzoic acid or sufentanil
  • contraindications to spinal or epidural anesthesia
  • bilateral inguinal herniorrhaphy
  • extremes of height and weight (BMI 20 or 35 kg/m2, height 150 cm or 185 cm)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
chloroprocaine 1% injectable solutionChloroprocaine 1% Injectable SolutionProspective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%. An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study. An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study.
Primary Outcome Measures
NameTimeMethod
The dose of chloroprocaine 1% needed for the individual patient for a sensory anesthesia block at or above the T6 dermatomestart of surgery

MLAD of chloroprocaine 1% with 2,5 mcg of sufentanil needed for the individual patient required for a sensory anesthesia at or above the T6 dermatome at the beginning of surgery with no additional epidural anesthesia required during surgery

Secondary Outcome Measures
NameTimeMethod
Time to micturitionFrom starting hour of spinal anesthesia to hour of first micturition after the end of surgery measured up to 6 hours after surgery

Time to micturition

Time for regression of two segmentsduring surgery

Time for regression of two segments

Time to dischargeFrom starting hour of spinal anesthesia to hour of discharge from hospital measured up to 6 hours after surgery

Time to discharge

Patient satisfaction with anesthesia method: questionnairepostoperatively,at moment of hospital discharge measured up to 6 hours after surgery

Patient satisfaction with simple questionnair (highly satisfied, satisfied, unsatisfied)

Peak block heightduring surgery

highest sensible block

Ambulation timeFrom starting hour of spinal anesthesia to hour of first ambulation after the end of surgery measured up to 6 hours after surgery

motor recovery

Incidence of side effects (perioperative hypotension, respiratory depression, neurologic deficits)perioperative

Incidence of side effects (perioperative hypotension, respiratory depression, neurologic deficits)

© Copyright 2025. All Rights Reserved by MedPath